

DATA SHEET

Hsa-miR-29b-3p fluoresceinated oligo probe

Catalog No.
HM29b-3p-100
 buffer

Description
 One vial of 0.650 ml of probe in hybridization

Analyte Specific Reagent. Analytical and performance characteristics are not established.

Doc. No. 932-HM29b-3p-100

Rev. B

Date of release: 11-Aug-2020

Description

The Hsa-miR-29b-3p probe has been designed from mature human miR-29b-3p sequence. This fluoresceinated probe is provided in a hybridization buffer for localization of miRNA in FFPE tissue by *In Situ* hybridization.

Specifications

The Hsa-miR-29b-3p identifies mature miR-29b-3p sequences in formalin-fixed, paraffin-embedded human tissues and/or freshly prepared frozen tissues by *in situ* hybridization. This probe does not react with normal human mRNA or nuclear DNA present in tissues.

Storage and Handling

Store the reagent at 2-8 °C. Do not freeze. Do not use the reagent after expiration date on vial. The reagent must be brought to room temperature before use. (Important! The presence of precipitates induces background staining).

Precautions:

For professional use, the probe contains formamide. Formamide is classified as a teratogen. Pregnant workers should keep exposure to a minimum. Avoid inhalation, ingestion, and contact with unprotected skin. If skin contact occurs, wash thoroughly with soap and water. For more information, refer to the Material Safety Data Sheet, which is available upon request.

Quality Control

Each lot of this miRNA probe is tested by *In-Situ* hybridization for Quality Control purposes. Refer to the BioGenex Quality Control Testing Conditions table for additional information.

References

1. Park SY, et al. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. *Nat Struct Mol Biol.* 2009;16:23–29
2. Pekarsky Y, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. *Cancer Res.* 2006; 66:11590–11593
3. Pekarsky Y, Croce CM. Is miR-29 an oncogene or tumor suppressor in CLL?. *Oncotarget.* 2010; 1:224–227
4. Mott JL, et al. mir-29 regulates Mcl-1 protein expression and apoptosis. *Oncogene.* 2007; 26:6133–6140.
5. Chung HJ, Choi YE, Kim ES, Han YH, Park MJ, Bae IH (2015). miR-29b-3p attenuates tumorigenicity and stemness maintenance in human glioblastoma multiforme by directly targeting BCL2L2. *Oncotarget.* 2015 Jul 30;6(21):18429-44
6. Xing LN, Wang H, Yin PH, Liu YJ, Chi YF, Wang YM, Peng W (2014) Reduced mir-29b-3p-3p expression up-regulate CDK6 and contributes to IgA nephropathy. *Int J Clin Exp Med.* 2014 Dec 15;7(12):5275-81.

BioGenex Quality Control Testing Conditions

Parameter	Conditions used
Control Tissue	Normal Colon (FB-HM29b-3p)
Tissue Type	Formalin-fixed, paraffin-embedded cancer tissues